Viracta Therapeutics
VIRX

$0.48

1.09%

Market Cap: 18.9M

About: Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Employees: 40

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,702 funds

Analysts bullish %

of 4 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

72% more capital invested

Capital invested by funds: $5.56M [Q4 2023] → $9.58M (+$4.02M) [Q1 2024]

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.32% less ownership

Funds ownership: 25.24% [Q4 2023] → 23.92% (-1.32%) [Q1 2024]

5% less funds holding

Funds holding: 42 [Q4 2023] → 40 (-2) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

733%

upside

Avg. target

1,566%

upside

High target

$13

2,607%

upside

4 analyst ratings

4 positive

100%

0 neutral

0 negative

Oppenheimer Hartaj Singh	2,190%upside $11	Outperform Maintained	23 May 2024
Oppenheimer Hartaj Singh	2,607%upside $13	Outperform Maintained	17 Apr 2024
HC Wainwright & Co. Robert Burns	733%upside $4	Buy Reiterated	16 Apr 2024
HC Wainwright & Co. Robert Burns	733%upside $4	Buy Reiterated	12 Mar 2024

See Analyst Rankings

Financial journalist opinion

Neutral

GlobeNewsWire

2 months ago

Viracta Therapeutics Announces New Employment Inducement Grants

SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each option vests over four years, with 25% of the shares subject to each option vesting on May 13, 2025, and the remaining 75% of the shares subject to each option vesting in equal monthly increments over the succeeding 36 months, in each case subject to the respective grantee's continuous service to Viracta through each vesting date. Each option has an exercise price of $0.804 per share, which is equal to the closing price per share of Viracta's common stock on May 14, 2024, the grant date of each option.

Neutral

GlobeNewsWire

2 months ago

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking.

Neutral

GlobeNewsWire

2 months ago

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL)

Negative

InvestorPlace

2 months ago

3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck

There are speculative ideas and then there are penny stocks under $1. Outside of forex trading or high-risk options trades, it generally doesn't get much more treacherous than this space.

Neutral

GlobeNewsWire

2 months ago

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 11:00 a.m. EDT.

Neutral

GlobeNewsWire

3 months ago

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable population) with a generally manageable safety profile -

$Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma$